UCB UCB presented positive results from two Phase 3 studies (BE HEARD I and BE HEARD II) evaluating bimekizumab's efficacy and safety in...

Sanofi has reduced the price of Lantus (insulin glargine injection) 100 Units/mL by 78%, which is Sanofi's most widely prescribed...